NCT00320411View on ClinicalTrials.gov

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 28, 2005

Primary Completion Date

April 1, 2009

Study Completion Date

April 1, 2009

Conditions
Neoplasms, Breast
Interventions
DRUG

lapatinib

Lapatinib 1500mg QD

Trial Locations (9)

791-0280

GSK Investigational Site, Ehime

814-0180

GSK Investigational Site, Fukuoka

241-0815

GSK Investigational Site, Kanagawa

701-0192

GSK Investigational Site, Okayama

329-0498

GSK Investigational Site, Tochigi

104-0045

GSK Investigational Site, Tokyo

113-8677

GSK Investigational Site, Tokyo

135-8550

GSK Investigational Site, Tokyo

Unknown

GSK Investigational Site

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY